The 200 patients on the trial improved the time they were in therapeutic range from 60% of the time to 75% which reduces the risk of complications.
Among the 200 individuals participating in the trial, their exposure to therapeutic levels increased from 60% to 75%, which should reduce the occurrence of associated risks.